Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024. For the full year 2025, total revenue was $12 billion, reflecting a 9% increase versus 2024 [32][33] - Non-GAAP net income for Q4 2025 was $1.3 billion, up 24% year-over-year, resulting in earnings per share of $5.03, a 26% increase compared to the prior year [37] - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [37] Business Line Data and Key Metrics Changes - Cystic fibrosis (CF) therapies generated a full year 2025 growth of 7% globally, with U.S. CF revenue growing 11% year-over-year [32][33] - CASGEVY achieved $54 million in revenue in Q4 and $116 million for the full year 2025, demonstrating continued momentum in patient initiations [34][35] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, with substantial growth in quarterly prescriptions since its launch [34] Market Data and Key Metrics Changes - The CF population has seen a 3% annual increase over the last five years, contributing to revenue growth [22] - In Europe, reimbursement for ALYFTREK has been secured in key countries, including the UK, Germany, and Italy, expanding access to CFTR modulators [22][23] - CASGEVY's reimbursement agreements in the U.S. have reached approximately 90% access for both Medicaid and commercial patients [23] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise [6][29] - The renal pipeline is emerging as a key growth engine, with povetacicept positioned to address significant unmet needs in IgA nephropathy and membranous nephropathy [10][29] - The company is focused on commercial execution and innovation to drive sustained growth across multiple serious disease areas [6][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on significant opportunities and drive sustained growth through commercial execution and innovation [6][40] - The guidance for 2026 anticipates total company revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [38] - The company expects combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as it continues to invest in its late-stage clinical pipeline [39] Other Important Information - The company has initiated a rolling BLA submission for povetacicept, with expectations for expedited regulatory review [11] - The company is committed to maintaining comprehensive patient support programs to facilitate access to its therapies [29] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to povetacicept - Management indicated that while BAFF/APRIL inhibitors may decrease IgG levels, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [42][44] Question: Guidance details for CF component and ALYFTREK - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, but did not break down specifics for ALYFTREK versus other products [49][51] Question: Payer access and reimbursement for povetacicept - Management reported positive engagements with payers, having conducted 74 meetings covering over 210 million lives, indicating strong interest in the upcoming products [55][60] Question: Expected results on proteinuria for povetacicept - Management emphasized the importance of magnitude of proteinuria response, referencing a 56% reduction seen in the RUBY-3 study as a benchmark for expected outcomes [62][64] Question: Differentiation of povetacicept in generalized myasthenia gravis - Management highlighted the engineered profile of povetacicept, which offers better potency and pharmacokinetics compared to existing treatments, positioning it as a promising option in a crowded market [68][70]

Financial Data and Key Metrics Changes - Vertex Pharmaceuticals has launched its fifth medicine for cystic fibrosis (CF), ElefTrex, which is now approved in the US and awaiting global approval [5][6] - The company has diversified its revenue streams, with new approvals in sickle cell disease and beta thalassemia through Kaschevi, the first CRISPR Cas9-based therapy approved [6][7] - The pipeline is described as broad and deep, with five programs in or nearing phase three [9] Business Line Data and Key Metrics Changes - The CF business continues to show growth, with more patients being identified and treated due to better medicines and longer patient lifespans [25][26] - ElefTrex is expected to treat a significant number of patients, with over 50% of children aged 6 to 11 achieving normal sweat chloride levels [30] - The acute pain launch of Gernavix is underway, with expectations for increased volumes and revenues as reimbursement and access improve [46] Market Data and Key Metrics Changes - The company has seen a headwind in Russia due to geopolitical issues and unauthorized copies of its medicine, but this situation is limited to Russia [37][38] - In the US, the CF business is expected to continue growing, driven by better treatment options and increased patient identification [25][26] Company Strategy and Development Direction - Vertex aims to replicate its success in CF across other disease areas, focusing on bringing more medicines through phase three and commercialization [12] - The company is committed to a long-term strategy, with a ten-year plan set to 2030 [10][12] - Vertex is focused on executing its current launches while preparing for future phase three readouts [13] Management's Comments on Operating Environment and Future Outlook - The management acknowledges a complicated macro environment with policy uncertainties but remains confident in regulatory science and its ability to navigate these challenges [15][17] - Vertex's exposure to Medicare and Medicaid is noted, with 10% and 23% of its business respectively, and the management is preparing for potential impacts from policy changes [18][19] - The company expects continued growth in its CF business, driven by new patient identification and treatment options [25][26] Other Important Information - Vertex has established offices in the Middle East to capitalize on the high prevalence of sickle cell disease and beta thalassemia in the region [105][106] - The company is focused on maintaining a balance between internal and external innovation, with a current pipeline of 40% external and 60% internal projects [110] Q&A Session Summary Question: How is the launch of ElefTrex going? - The launch is progressing well, with rapid uptake among newly eligible patients and those returning to therapy [32] Question: What is the company's strategy regarding the pain market? - Vertex will maintain a specialty sales force and will not expand into primary care settings, focusing on acute and neuropathic pain [53][56] Question: What are the expectations for the Gernavix launch? - The company anticipates increased volumes and revenues in the second half of the year as reimbursement and access improve [46] Question: How does Vertex view the competitive landscape for its new therapies? - Vertex believes it can achieve best-in-class status despite not being first to market, focusing on efficacy, safety, and breadth of indications [86] Question: What is the company's approach to capital allocation? - Vertex prioritizes innovation, with a focus on both internal and external projects, and has a share buyback program in place [110][111]